East India Pharmaceutical Works Limited
- Unlisted share
- Healthcare
- ISIN INE254X01017
At a glance
Sales
FY26
₹274 Cr
+0.7%on FY25What the company earned from its customers in the year.
Profit
FY26
₹3.33 Cr
+50.7%on FY25What was left after every cost and tax was paid.
Net worth
FY26
₹60.62 Cr
What the owners would have left on paper if every debt was repaid.
From the company's published figures; sources are beside each figure further down the page.
Key details
- Company
- East India Pharmaceutical Works Limited
- ISIN
- INE254X01017
- Sector
- Healthcare
- Type of share
- Unlisted equity share
- Indicative price per share
- On request
- Price last updated
- 12 Oct 2026
- Minimum quantity
- Confirmed by the desk
- How you hold it
- In your own demat account
- Enquiries
- GrowFast desk, on WhatsApp
Indicative prices, illiquid shares. Prices are indicative and can change without notice. Unlisted shares are illiquid: you may not be able to sell when you want to, or at the price shown.
Company
About East India Pharmaceutical Works Limited
East India Pharmaceutical Works Limited is a Kolkata drug maker founded in 1936 that makes and markets branded formulations, best known for Enteroquinol (an anti-amoebic), Tonoferon (an iron tonic), Vitazyme and Pyrigesic, along with a few herbal products. It has a formulation plant at Sarsuna and an API plant at Durgapur in West Bengal and employs about 1,500 people. It is an unlisted public company with roughly 1,500 shareholders; five individual promoters hold about 26% and two of them are the managing directors.
Written from: eastindiapharma.org, icra.in, eastindiapharma.org
Financials
Ask for the full annual report.
The figures on this page are the headline numbers. The desk can share the latest annual report and anything published since.
Ask for the financials- Sector
- Healthcare
- ISIN
- INE254X01017
- Registered office
- Kolkata, West Bengal
- Promoters
- Debarshi Duttagupta (9.76%), Satarupa Mukherjee (7.70%), Nabamita Duttagupta (3.98%), Indrani Sen (2.81%), Sanghamitra Duttagupta (1.64%)
- Key people
- Chairman: Probir Roy; Managing Directors: Debarshi Duttagupta and Satarupa Mukherjee; Company Secretary: Jayeeta Sarkar
- Employees
- 1,526 people
- Face value per share
- ₹10
- Ordinary shares subscribed and paid up
- 66,74,858 shares
- CIN
- U24231WB1936PLC008598
- Official website
- eastindiapharma.org
Read from: Annual Report & Accounts 2025-26 (company website), unless another source is shown on a card.
Key data
What the numbers mean
The ratios buyers look at, each said in plain words.
Profit margincalculated
1.2%
Out of every ₹100 of sales, ₹1.2 was left as profit.
Return on equitycalculated
5.5%
For every ₹100 of the owners' money, the company made ₹5.5 of profit in the year.
Debt to equitycalculated
0.86×
The company has borrowed ₹0.86 for every ₹1 of its owners' money.
- Indicative price
- On request
- No. of shares
- 66,74,858
- EPS
- ₹4.98
- Book value per share
- ₹90.81
- Face value
- ₹10
Figures marked “calculated” are worked out by GrowFast from its indicative price and the company's published figures for FY2025-26. They move with the price, and they are arithmetic, not a valuation.
Figures in ₹ crore
Financials
East India Pharmaceutical Works Limited. As published in the company's audited reports. GrowFast has not audited them.
Sales, year by year
₹ crore. The darkest bar is the latest year.
FY24 to FY26: ₹250 Cr to ₹274 Cr.
Profit, year by year
₹ crore, after tax. A bar below the line is a loss.
FY23 to FY26: ₹1.69 Cr to ₹3.33 Cr.
| Particulars | FY23 | FY24 | FY25 | FY26Latest |
|---|---|---|---|---|
| Revenue from operations | n/a | 249.81 | 271.69 | 273.54▲1% |
| Other income | n/a | 0.13 | 0.15 | 1.89▲1143% |
| Total income | n/a | 249.94 | 271.84 | 275.44▲1% |
| Depreciation and amortisation | n/a | 2.58 | 2.34 | 2.1▼10% |
| Finance costs | 4.69 | 5.47 | 6.17 | 6.09▼1% |
| Profit before tax | 2.43 | 4.54 | 4.19 | 5.93▲41% |
| Profit after tax | 1.69 | 3.87 | 2.21 | 3.33▲51% |
| Earnings per share (basic) (₹) | n/a | 5.8 | 3.31 | 4.98▲50% |
Rupees crore unless marked, standalone. The change shown is the latest year against the year before. Read from: Annual Report & Accounts 2024-25 (company website), Annual Report & Accounts 2025-26 (company website).
Credit rating. [ICRA]BBB- (Stable) long term; [ICRA]A3 short term, on ₹55.13 crore of bank facilities (9 March 2023) ICRA rating rationale, 9 March 2023
Ownership
Shareholding pattern
Who owns the company
As of 31 March 2026
54.3%Public: resident individuals / HUF
- Largest holder
- 54.3%
- Top 3 together
- 97.0%
- Holders named
- 6
- Public: resident individuals / HUF54.29%
- Promoters (five individuals)25.89%
- Others (IEPF)16.79%
- Public: bodies corporate2.53%
- Public: foreign nationals0.48%
- Public: non-resident Indians0.02%
- Total100.00%
Read from: Annual return (Form MGT-7) for FY2025-26 (company website)
Leadership
Management
Probir Roy
Chairman
Debarshi Duttagupta
Managing Director
Satarupa Mukherjee
Managing Director
Jayeeta Sarkar
Company Secretary
Dr. Abhijit Banerjee
Director
Dr. Tapas Raychaudhury
Director
Dilip Samadar
Director
Indrani Sen
Director
Sanghamitra Duttagupta
Director
Read from: Annual Report & Accounts 2025-26 (company website)
Corporate calendar
Events
- 11 Sept 2026AGM89th AGM (by video conference) to adopt FY2025-26 accounts and declare a dividend of ₹0.80 per share; record date 4 September 2026Open
- 7 Aug 2026Board meetingBoard approved FY2025-26 accounts and recommended an 8% dividend (₹0.80 per share)Open
- 9 Mar 2023RatingICRA reaffirmed [ICRA]BBB- (Stable) / [ICRA]A3 and raised the rated amount to ₹55.13 croreOpen
Reports and filings
Annual reports and results
Each link opens the document where its publisher keeps it.
Before you buy
Six things to check on any unlisted share.
The same list applies to every stock. None of it is advice on this one.
The company's latest financials
Revenue, profit and debt for the last three years, from its audited annual report. Ask the desk for the most recent set.
What the price implies
Compare the price per share with earnings and book value per share, and with listed companies in the same business.
Whether a listing is planned
A company may file for an IPO, delay it or never list. A listing, its timing and its price are never certain.
How you would sell
There is no exchange for these shares. You sell by finding a buyer, which can take time and may be at a lower price.
Lock-in after a listing
Shares bought before an IPO are usually locked in for a period after the company lists. Confirm the current rule before you buy.
Tax on your gains
Unlisted shares are taxed differently from listed ones. Check your position with a tax adviser.
Questions
What buyers ask about this stock.
Not answered here? Ask the desk.
Inquire about East India Pharmaceutical Works Limited on WhatsAppIs the price shown for East India Pharmaceutical Works Limited final?
No. It is an indicative price per share. The desk confirms the price and the quantity available when you inquire, and the confirmed price is the one you deal at.
How do I buy these shares?
Press Inquire. It opens a WhatsApp chat with the desk, with this stock already named. After the price and quantity are agreed, a 10% advance locks the deal. Once your KYC is complete you pay the balance, and the shares are transferred to your demat account.
Do I pay anything on this website?
No. No payment is taken and no order is placed on this site. Payment details are shared by the desk only after the deal is agreed.
What do I need before I can buy?
A demat account in your name and the documents for KYC: your identity and demat account details are verified before any deal, as the regulations require.
Can I sell my East India Pharmaceutical Works Limited shares to GrowFast?
GrowFast buys as well as sells. Press Inquire and tell the desk how many shares you hold; it will come back with what it can offer.
How do I sell East India Pharmaceutical Works Limited shares I already hold?
Tell the desk how many you hold. If a price is agreed, you transfer the shares from your demat account with a delivery instruction to your depository participant (a DIS, or its online equivalent), and payment follows as agreed with the desk.
Is there a lock-in if the company lists?
Shares held before an IPO are generally locked in for a period after the listing under SEBI's rules, which have changed over time. Ask the desk for the rule that applies today before you buy.
Is buying unlisted shares legal in India?
Yes. Shares of an unlisted company can be bought and sold privately and are transferred between demat accounts. They are not traded on a stock exchange, so the protections of an exchange do not apply.
What is the minimum I can buy?
It differs by stock and by what the desk holds at the time. The desk confirms the minimum quantity when you inquire.
What is an ISIN?
The 12-character code that identifies a security. It is how your depository knows exactly which share is being transferred to your demat account.
Why are unlisted shares riskier than listed ones?
Prices are indicative and can change without notice. Unlisted shares are illiquid: you may not be able to sell when you want to, or at the price shown.
Similar stocks
More in Healthcare
- Anglo-French Drugs & Industries Ltd₹1,585.24 · ₹179 Cr · P/E 7.8
- API Holdings Ltd (PharmEasy)₹6.46 · ₹4,539 Cr
- Dantech Digital Dental Solutions Private Limited₹445.50
- Down Town Hospital Limited₹371.25
- Gynofem Healthcare and Pharmaceutical₹63.36
- Hicks Thermometers India Limited₹1,633.50 · ₹45 Cr · P/E 8.1
Risk disclosure
Prices on this site are indicative, quoted per share, and are not an offer to buy or sell. The price and quantity for any deal are confirmed by GrowFast's desk at the time you deal.
Unlisted, pre-IPO and delisted shares are not traded on a stock exchange. They are illiquid, their prices can move sharply, and you may be unable to sell them when you wish or at all. A company that is expected to list may not do so.
Nothing on this site is investment advice or a promise of returns. Past prices do not predict future prices. Consider your own circumstances, and take independent advice, before you invest.
Inquire opens a WhatsApp chat with GrowFast. No payment is taken and no order is placed on this site.
GrowFast is not affiliated with, sponsored by or endorsed by East India Pharmaceutical Works Limited. Its name and logo belong to their owner and are shown only to identify the company. Figures about it come from published sources and have not been audited by GrowFast. See the Terms and Conditions.